The López-Belmonte family increase their interest in ROVI to 63.1%

The majority shareholders of Laboratorios Farmacéuticos Rovi, S.A. increase their interest in ROVI to 35,383,462 shares


The López-Belmonte family, the principal shareholders of Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”), have increased their interest in the company’s share capital to 63.107% through their investment vehicle Norbel Inversiones, S.L., which has thus become the direct holder of 35,383,462 of ROVI’s shares.

Juan López-Belmonte Encina said: This increase in the interest held by Norbel Inversiones, S.L. in ROVI’s share capital reflects the López-Belmonte family’s clear bet on the company and our confidence in ROVI’s business model and its future prospects”.

No votes yet
 
Relacionados
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” o la “Compañía”) (www.rovi.es) ha anunciado hoy que la Comisión Europea ha autorizado la...
3 min
15/02/2022
Madrid – 28 de enero de 2022 El pasado mes de mayo ROVI firmó un acuerdo de financiación con el Centro para el Desarrollo Tecnológico...
2 min
28/01/2022
ROVI recibe la opinión positiva del CHMP para Okedi® como tratamiento de la esquizofrenia
Laboratorios Farmacéuticos Rovi, compañía farmacéutica paneuropea especializada dedicada a la investigación, desarrollo, fabricación y...
4 min
17/12/2021